Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers

被引:73
作者
Arber, DA [1 ]
机构
[1] City Hope Natl Med Ctr, Div Pathol, Duarte, CA 91010 USA
来源
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY | 2002年 / 10卷 / 02期
关键词
immunohistochemistry; formalin-fixation; breast carcinoma;
D O I
10.1097/00022744-200206000-00015
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Prolonged formalin fixation is known to reduce the immunohistochemical reactivity of many paraffin section antibodies. Before the common use of heat induced epitope retrieval methods, vimentin reactivity was proposed as a marker of antigen preservation. To evaluate the effect of formalin fixation on breast tumor markers, multitumor blocks of tissue fixed in formalin for varying time intervals from 33 different infiltrating breast carcinomas were analyzed for the expression of estrogen receptor (ER), progesterone receptor (PR), c-erb-B2, Ki-67, p27, and vimentin. The mean/median length of the longest fixation time per specimen was 53/42 days (range 7 days-154 days). Formalin fixation did not significantly reduce immunoreactivity for Ki-67, p27, or vimentin, even in tissue fixed for 154 days. Of 23 ER-positive cases, a significant reduction in immunoreactivity (2 grades or more) was identified in three samples, occurring at 57 to 64 days. For 21 PR-positive cases, only one showed a significant reduction (,from 3+ to 1+) at 120 days. Of nine c-erb-B2 positive (2+ or 3+) cases, four became negative (1+ or 0) at 20, 42, 49, and 99 days. The immunoreactivity of some breast prognostic markers is reduced by formalin over-fixation, but only after extensive fixation that may not be clinically relevant. The loss of antigen preservation is not accompanied by a loss of vimentin immunoreactivity making vimentin a suboptimal marker for ER, PR, or c-erb-B2 preservation.
引用
收藏
页码:183 / 186
页数:4
相关论文
共 11 条
[1]  
[Anonymous], ADV PATHOL LAB MED
[2]  
[Anonymous], BREAST J
[3]  
Arber JM, 1996, APPL IMMUNOHISTOCHEM, V4, P241
[4]  
BATTIFORA H, 1990, LAB INVEST, V63, P722
[6]  
ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300
[7]   HER-2/neu testing in breast carcinoma:: A combined immunohistochemical and fluorescence In situ hybridization approach [J].
Ridolfi, RL ;
Jamehdor, MR ;
Arber, JM .
MODERN PATHOLOGY, 2000, 13 (08) :866-873
[8]  
Sheibani K, 1984, Semin Diagn Pathol, V1, P235
[9]   STRATEGIES FOR IMPROVING THE IMMUNOHISTOCHEMICAL STAINING OF VARIOUS INTRANUCLEAR PROGNOSTIC MARKERS IN FORMALIN-PARAFFIN SECTIONS - ANDROGEN RECEPTOR, ESTROGEN-RECEPTOR, PROGESTERONE-RECEPTOR, P53 PROTEIN, PROLIFERATING CELL NUCLEAR ANTIGEN, AND KI-67 ANTIGEN REVEALED BY ANTIGEN RETRIEVAL TECHNIQUES [J].
TAYLOR, CR ;
SHI, SR ;
CHAIWUN, B ;
YOUNG, L ;
IMAM, SA ;
COTE, RJ .
HUMAN PATHOLOGY, 1994, 25 (03) :263-270
[10]   Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message [J].
Tubbs, RR ;
Pettay, JD ;
Roche, PC ;
Stoler, MH ;
Jenkins, RB ;
Grogan, TM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2714-2721